



PRESS RELEASE

FOR IMMEDIATE RELEASE

DNAVISION IS THE FIRST EUROPEAN SERVICE COMPANY TO BE OFFICIALLY TRAINED TO THE LATEST AFFYMETRIX SNP 6.0 GENECHIP.

Brussels, August 27th 2007 – **DNAVision** announced today that he has fulfilled training in the new Affymetrix® Genome-Wide Human SNP Array 6.0 which features **1.8 million genetic markers**. DNAVision is the **first full-service pharmacogenomic laboratory** to provide this powerful genotyping solution in Europe.

The high price-performance value of the SNP Array 6.0 enables researchers to design association studies with larger sample sizes in the initial scan and replication phases, thereby significantly increasing the overall genetic power of their studies.

“DNAVision is proud to be the **first European pharmacogenomic DNA testing laboratory** to provide this innovative tool. Genetic association studies are a powerful method for uncovering the basis of complex human disease and represent a valuable aspect in understanding variability in response to therapeutics. By combining our high quality standards (**ISO17025 accredited, GLP compliant**) with this high-performing system, DNAVision will provide his customers with quality data, giving them the information they need to solve complete research programs” said Jean-Pol Detiffe, CEO of DNAVision SA.

About DNAVision

DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment (First European laboratory to be ISO17025 accredited). DNAVision is a spin-off of University of Brussels and Institute of Pathology and Genetics. More information on DNAVision’s service portfolio can be found on www.dnavision.be

Further information:

Jean-Pol Detiffe
DNAVision SA
Tel. +32 71 378 527
Fax. +32 71 378 501
info@dnavision.be
www.dnavision.be